Immutep raises A$10M via private placement, underwritten entitlement offer
Immutep has announced an equity financing to raise gross proceeds of approximately A$10M, or $7M comprising the following: a private placement of 190.5 million new fully paid ordinary shares in the Company to multiple new and existing Australian and other institutional and professional investors at an issue price of A$0.021 per Share, raising a total of A$4M before transaction-related expenses; and a 1 for 11.8 fully underwritten pro rata non-renounceable entitlement offer of new Shares at the Offer Price to raise approximately A$6M. Only persons holding ordinary shares of the Company and having a registered address in Australia or New Zealand are entitled to participate in the Entitlement Offer. U.S. persons who own, directly or indirectly, ordinary shares or American Depositary Shares of the Company may not participate in the Entitlement Offer. These capital raising transactions are subject to customary closing conditions in Australia. Settlement of the Shares in the Private Placement is expected to occur on July 16, 2019 and in the Entitlement Offer in early August 2019. The Company will use the proceeds received from the Private Placement and the Entitlement Offer to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease. This includes the ongoing clinical development of eftilagimod alpha, via its TACTI-mel, TACTI-002, and INSIGHT clinical studies, development of IMP761 and for general corporate purposes. Subject to sufficient and clinically meaningful data from the Company's most advanced and potentially pivotal clinical trial, AIPAC, the funds raised may also be applied to pursue the appropriate regulatory pathways for efti and to explore ways to bridge Immutep's research efforts in metastatic breast cancer to the United States.